Showing results (301-310 of 2,409) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|June 8, 2013
Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-releaseKrithika Rajagopalan, Ken O'Day, Kellie Meyer, et al.Journal of Medical Economics|November 6, 2013
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemiaAnnie Guérin, Lei Chen, Katherine Dea, et al.Journal of Medical Economics|November 13, 2013
Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancerT Rautenberg, U Siebert, D Arnold, et al.Journal of Medical Economics|October 1, 2013
Characterizing the financial burden of pulmonary arterial hypertension within an integrated healthcare delivery systemSamuel Johnson, Thomas Delate, Adrian Boka, et al.Journal of Medical Economics|October 10, 2013
Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS studyL Abramowitz, N Béziaud, L Labreze, et al.Journal of Medical Economics|July 10, 2013
Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patientsAmit Sharma, Markus Ketteler, Thomas S Marshall, et al.Journal of Medical Economics|July 10, 2013
The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort studyElizabeth L Eby, Kristina S Boye, Maureen J LageJournal of Medical Economics|July 13, 2013
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in FinlandThomas R Einarson, Hanna Pudas, Roman Zilbershtein, et al.Journal of Medical Economics|July 26, 2013
Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillationAlpesh Amin, Michael Stokes, Ning Wu, et al.Journal of Medical Economics|October 14, 2011
Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPDShawn X Sun, Maryna Marynchenko, Ritesh Banerjee, et al.Pageof 241